DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20175872

Fertility and ulipristal acetate case report of two spontaneous pregnancies in the same patient following one cycle of treatment

Joana Lopes Pereira, Pedro Viana Pinto, Ana Rosa Costa, Jorge Beires

Abstract


Ulipristal acetate (UPA) is an oral selective progesterone receptor modulator. It is one of the most recent alternatives in the management of symptomatic fibroids and its safety and effectiveness have already been demonstrated in several studies. Nevertheless, there is few evidence regarding its use in the subgroup of women who experience fertility issues and desire to conceive. The authors report a case of a 39- years-old woman with abnormal uterine bleeding and anemia. She had had an uncomplicated pregnancy some years before and was trying to have a second child. She was treated for 3 months with UPA, at a daily dose of 5 mg, per os, followed by a ressectoscopic myomectomy. After five months, she conceived spontaneously and had an uneventful pregnancy. She then remained asymptomatic and almost two years after she was pregnant again. This case supports the idea that UPA is a valid alternative in patients still have a desire to conceive and thus want to avoid surgery. Even tough larger studies on the subject are required, UPA may become very important role in the management of fibroids in the infertility context.


Keywords


Fibroids, Pregnancy, Ulipristal acetate

Full Text:

PDF

References


Baird DD, Dunson DB. Why is parity protective for uterine fibroids? Epidemiology. 2003;14(2):247-50.

Islam MS, Protic O, Giannubilo SR, Toti P, Tranquilli AL, Petraglia F et al. Uterine leiomyoma: available medical treatments and new possible therapeutic options. J Clin Endocrinol Metab. 2013;98(3):921-34.

Guo XC, Segars JH. The impact and management of fibroids for fertility: an evidence-based approach. Obstet Gynecol Clin North Am. 2012;39(4):521-33.

Bulletti C, De Ziegler D, Polli V, Flamigni C. The role of leiomyomas in infertility. J Am Assoc Gynecol Laparosc. 1999;6(4):441-5.

Donnez J, Donnez O, Dolmans MM. Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Expert Opin Drug Saf. 2016;15(12):1679-86.

Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future. Hum Reprod Update. 2016;22(6):665-86.

Luyckx M, Squifflet JL, Jadoul P, Votino R, Dolmans MM, Donnez J. First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids. Fertil Steril. 2014;102(5):1404-9.